PTGS2 and major depressive disorder: Sethi and colleagues provide an important and timely review of pre-clinical and clinical studies investigating the use of COX-2 inhibitors across multiple psychiatric disorders including major depressive disorder, schizophrenia, bipolar affective disorder, autism spectrum disorder (ASD), and obsessive compulsive disorder (OCD).